The need for better evidence to evaluate the health & economic benefits of India's Rashtriya Swasthya Bima Yojana

被引:13
|
作者
Nandi, Arindam [1 ,3 ]
Holtzman, E. Phoebe [2 ]
Malani, Anup [2 ]
Laxminarayan, Ramanan [1 ,3 ]
机构
[1] Ctr Dis Dynam Econ & Policy, Washington, DC 20005 USA
[2] Univ Chicago, Sch Law, Chicago, IL 60637 USA
[3] Publ Hlth Fdn India, New Delhi, India
关键词
Financial risk protection; impact evaluation; RSBY; social health insurance; RANDOMIZED CONTROLLED-TRIALS; HOSPITAL INSURANCE; CARE; IMPACT; EXPENDITURES; PAYMENTS; DESIGN; ACCESS; INCOME; URBAN;
D O I
10.4103/0971-5916.169194
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this review the existing evidence on the impact of Rashtriya Swasthya Bima Yojana (RSBY) is discussed in the context of international literature available on health insurance. We describe potential pathways through which health insurance can affect health and economic outcomes, discuss evidence from other developing countries, and identify potential biases and inconsistencies in existing studies on RSBY impact. Given the relatively recent introduction of RSBY, lack of quality, verifiable data on utilization patterns, and the absence of reliable evaluation studies, there is a need to exercise caution while assessing the merits of the programme. Considering the enormous potential and cost of the programme, we emphasize the need for a rigorous impact evaluation of RSBY. It will not only help capture the real impact of the scheme, but may also be able to estimate the extent of systemic inefficiencies at the level of the consumer.
引用
收藏
页码:383 / 390
页数:8
相关论文
共 21 条